Onsdag 5 Februari | 18:03:32 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-11-20 08:00 Kvartalsrapport 2025-Q3
2025-08-20 08:00 Kvartalsrapport 2025-Q2
2025-05-22 N/A Årsstämma
2025-05-19 08:00 Kvartalsrapport 2025-Q1
2025-02-20 N/A Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm.
2024-12-30 14:00:00

The number of shares and votes in Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) has changed as a result of the issue and repurchase of 854,430 class C shares in accordance with the Board of Directors’ resolution announced on 28 November 2024 and registered with the Swedish Companies Registration Office on 3 December 2024

As of 30 December 2024, the last trading day of the month, the total number of shares in Cinclus Pharma amounts to 47,392,219, of which 46,537,789 are ordinary shares and 854,430 are class C shares. The total number of votes amounts to 46,623,232, of which the ordinary shares correspond to 46,537,789 votes and the class C shares correspond to 85,443 votes. The company's share capital has through the issue increased by approximately SEK 16,588, from approximately SEK 903,451 to approximately SEK 920,039.

Ordinary shares entitle the holder to one vote per share, while class C shares entitle the holder to 1/10 vote. The C-shares will be held by the company to be used in the future for its long-term share-based incentive programs.